A patient has been diagnosed with COPD. Using both mMRC and CAT, the nurse practitioner has determined that the patient falls into GOLD group B. The nurse practitioner will prescribe or ensure the patient is taking:

Rationale: A. ICS-LABA combinations are no longer the primary recommendation for GOLD Group B patients who do not have a history of frequent exacerbations. Inhaled corticosteroids are associated with an increased risk of pneumonia in COPD patients and should be reserved for those with high blood eosinophil counts or frequent hospitalizations. Group B management focuses on maximizing bronchodilation rather than suppressing eosinophilic inflammation. B. While a single LAMA or LABA was previously the standard for Group B, updated GOLD guidelines now emphasize the use of dual bronchodilation. Using only one long-acting agent may not sufficiently address the high symptom burden characterized by a CAT score ≥ 10. Combining two classes of bronchodilators provides superior improvement in lung function and symptoms compared to monotherapy for symptomatic patients. C. Triple therapy containing an ICS, LAMA, and LABA is excessive for a Group B patient who is characterized by a low risk of exacerbations. This intensive regimen is reserved for Group E patients who continue to experience exacerbations despite dual bronchodilator therapy. Starting with triple therapy exposes the patient to unnecessary medication side effects and increased costs without providing additional benefit for their specific GOLD classification. D. GOLD Group B patients have a high symptom burden but a low risk of exacerbations, making dual bronchodilation with a LAMA and LABA the preferred initial treatment. This combination works through different pathways to maximize airway caliber and reduce dyspnea during daily activities. A SABA is always provided as a rescue medication to manage any acute breakthrough symptoms that occur between scheduled doses.